Tonix Pharmaceuticals Announces Outcome of Interim Analysis of Phase 3 RALLY Study of TNX-102 SL for the Management of Fibromyalgia

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/22/2026

1. META
2. NVDA
3. SPY
4. USO
5. GS
6. PSKY
7. VRTX
8. LGND
9. ONON
10. DCOY

Go back to Tonix Pharmaceuticals Announces Outcome of Interim Analysis of Phase 3 RALLY Study of TNX-102 SL for the Management of Fibromyalgia
TONIX PHARM HLDG (NASDAQ: TNXP) Delayed: 10.90 +0.18 (1.68%)
Previous Close $10.72    52 Week High $7.95 
Open $10.93    52 Week Low $0.40 
Day High $11.19    P/E N/A 
Day Low $10.83    EPS $-5.33 
Volume 281,896